Combination of HIV, hepatitis C, MS drugs might resolve COVID-19 infection
Combination therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin appears to improve symptoms and shorten hospital stays for people with mild to moderate COVID-19. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 8, 2020 Category: Consumer Health News Source Type: news
Antiviral Trio Shows Mettle Against COVID-19
FRIDAY, May 8, 2020 -- A triple whammy of three antiviral drugs shows promise in fighting mild to moderate COVID-19, a new, small study suggests.
Two weeks of interferon beta-1b, lopinavir-ritonavir and ribavirin -- along with standard care -- was... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 8, 2020 Category: General Medicine Source Type: news
The Lancet: New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial
(The Lancet) A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomized trial of this triple combination therapy involving 127 adults (aged 18 and older) from six public hospitals in Hong Kong. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 8, 2020 Category: Infectious Diseases Source Type: news
Australian hydroxychloroquine trials continue despite studies showing no benefit to coronavirus patients
Clinical findings of the antimalarial drug have been inconsistent, with one study showing a higher mortality rate when it was administered aloneSign up for Guardian Australia ’s daily coronavirus emailDownload the free Guardian app to get the most important news notificationsThe results of early studies from the US and China, which show disappointing results in the use of an antimalarial drug and an anti-retroviral drug in treating Covid-19, will not impact trials of the drug under way in Australia, researchers say.To date more than 300 clinical trials in humans are under way around the world to investigate treatments fo...
Source: Guardian Unlimited Science - April 27, 2020 Category: Science Authors: Melissa Davey Tags: Coronavirus outbreak Infectious diseases Science Drugs Health Australia news Medical research Queensland Source Type: news
Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis, MedRxiv, 2020
Conclusions: There is no evidence showing the effectiveness of antiviral agents for children with COVID-19, and the clinical efficacy of existing antiviral agents is still uncertain. We do not suggest clinical routine use of antivirals for COVID-19 in children, with the exception of clinical trials. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 24, 2020 Category: Consumer Health News Source Type: news
Lopinavir/Ritonavir, Umifenovir Ineffective for Mild COVID - 19
Rate of positive - to - negative conversion of SARS - CoV - 2 did not differ for drug therapy versus standard care (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 23, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news
Lopinavir/Ritonavir, Umifenovir Ineffective for Mild COVID-19
THURSDAY, April 23, 2020 -- For patients hospitalized with mild/moderate COVID-19, lopinavir/ritonavir (LPV/r) or umifenovir (Arbidol) monotherapy offers little benefit, according to a study published online April 17 in Med.
Yueping Li, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2020 Category: Pharmaceuticals Source Type: news
Lopinavir/ritonavir and Arbidol not effective for mild-to-moderate COVID-19 in adults
An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol - antivirals that are used in some countries against HIV-1 and to treat influenza, respectively - as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care. (Source: World Pharma News)
Source: World Pharma News - April 20, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Lopinavir/ritonavir and Arbidol not effective for mild-to-moderate COVID-19 in adults
(Cell Press) An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care. The findings appeared April 17 in Med, a new medical journal published by Cell Press. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 20, 2020 Category: Infectious Diseases Source Type: news
Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19
There is currently no strong evidence of efficacy of Lopinavir/ritonavir in the treatment of COVID-19. The limited studies identified, which overall are subject to methodological flaws. Several ongoing trials of Lopinavir/ritonavir are currenty recruiting. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 14, 2020 Category: Consumer Health News Source Type: news
Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19, CEBM
There is currently no strong evidence of efficacy of Lopinavir/ritonavir in the treatment of COVID-19. The limited studies identified, which overall are subject to methodological flaws. Several ongoing trials of Lopinavir/ritonavir are currenty recruiting. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 14, 2020 Category: Consumer Health News Source Type: news
Key China Coronavirus Hospital Says HIV Drug Beneficial to Patients Key China Coronavirus Hospital Says HIV Drug Beneficial to Patients
Chinese doctors at the primary hospital treating severe coronavirus patients in the city of Wuhan said they have been using the HIV drug Kaletra since January and believe it is beneficial, despite a previous study that it was ineffective.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 10, 2020 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
lopinavir and ritonavir (Kaletra): Potential COVID-19 Drug
Title: lopinavir and ritonavir (Kaletra): Potential COVID-19 DrugCategory: MedicationsCreated: 3/12/2001 12:00:00 AMLast Editorial Review: 4/8/2020 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 8, 2020 Category: Infectious Diseases Source Type: news
Update on treatments and vaccines against COVID-19 under development
At present, potential treatments for COVID-19 undergoing clinical trials are remdesivir (investigational), lopinavir/ritonavir, chloroquine& hydroxychloroquine, systemic interferons and monoclonal antibodies with activity against components of the immune system. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 2, 2020 Category: Consumer Health News Source Type: news
A Drug Developed to Fight Ebola Could Hold Hope for Coronavirus Treatment
Last year, when I visited the town of Beni, in the Democratic Republic of the Congo (DRC), people did not shake hands. Bottles of disinfectant and buckets of chlorinated water were at the entrance of every business. Misinformation spread across social networks and on news-sites, and treatment centers in the northeastern province of North Kivu were being attacked by armed militias.
At the time, Beni was one of the centers of a devastating Ebola outbreak, the second most deadly in world history. According to the World Health Organization, almost 3,500 people were sickened by the virus, and more than 2,000 died, a case fatali...
Source: TIME: Health - April 1, 2020 Category: Consumer Health News Authors: Nicolas Niarchos Tags: Uncategorized COVID-19 Source Type: news
